News | June 06, 2013

New Data Shows Sustained Blood Pressure Reduction With Boston Scientific Vessix Renal Denervation System

Boston Scientific Vessix Renal Denervation System Hypertension Therapies

June 6, 2013 — Boston Scientific Corporation reported interim data from the REDUCE-HTN clinical program, which demonstrated a significant and sustained reduction in the blood pressure of patients treated with the Vessix Renal Denervation System. Data on the first 41 subjects enrolled in the REDUCE-HTN clinical program were presented today at the annual EuroPCR Scientific Program in Paris by Joachim Schofer, M.D., of the Hamburg University Cardiovascular Center.

Renal denervation with the Vessix System is a minimally-invasive procedure in which a balloon catheter is fed into the arterial vascular system and positioned in the renal arteries, the major blood vessels that lead to the kidneys. The physician then delivers low-power radiofrequency (RF) energy to disrupt the nerves surrounding the renal arteries in which hyperactivity leads to uncontrolled high blood pressure.

"Tens of thousands of patients worldwide have blood pressure that is high and uncontrolled, putting them at significantly increased risk for a variety of cardiovascular diseases, including heart attack, stroke and kidney failure," said Professor Horst Sievert, M.D., Ph.D., director of the CardioVascular Center Frankfurt, Sankt Katharinen Hospital, in Frankfurt, Germany, and principal investigator in the REDUCE-HTN clinical program. "The interim data from REDUCE-HTN demonstrate that renal denervation with the Vessix System offers a significant and sustained blood pressure reduction in patients with uncontrolled hypertension. The familiar over-the-wire balloon platform of the Vessix System, the short procedure time and precise bipolar approach offer a significant step forward in the treatment of this challenging condition."

The REDUCE-HTN clinical program is evaluating the ability of the Vessix System to reduce blood pressure at six months as compared to the pre-treatment baseline blood pressure. Patients enrolled in the program are required to have a systolic blood pressure of at least 160 mmHg despite taking three or more antihypertensive medications.

Interim data highlights include:

  • All patients underwent successful bilateral renal denervation treatment
  • At the primary endpoint of six months, patients experienced a significant 27.6 mmHg reduction in systolic blood pressure (p<0.0001)
  • No device-related adverse events or procedural renal artery complications were reported
  • Long term efficacy was demonstrated, with a sustained 28.4 mmHg reduction in systolic blood pressure in the subset of patients for whom 12-month data are available
  • Demonstrated success in treating various anatomies, including accessory renal arteries
  • Demonstrated short renal denervation procedural time

 

"We believe that the familiar balloon catheter design of the Vessix System, intuitive user interface and unique bipolar technology make it the ideal choice for physicians," said Jeff Mirviss, president, Peripheral Interventions, Boston Scientific. "The interim REDUCE-HTN data support the expected long-term benefit of the Vessix System in reducing blood pressure, and we're excited to bring this advanced technology to physicians and their patients."

The Vessix System is a highly-differentiated, advanced renal denervation system that features an intuitive push-button interface, a short 30-second treatment time and an over-the-wire, balloon-based approach familiar to most cardiac and vascular specialists. The Vessix System has both CE Mark and TGA approval and is immediately available for sale in Europe, the Middle East, Australia, New Zealand and select markets in Asia. The Vessix System is not approved for use or sale in the United States.

 

For more information: www.bostonscientific.com

 

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init